Meet The Company Creating Novel Products For The Treatment Of ADHD


Sign up for this week’s All Access giveaway here

Shane Schaffer, CEO of Cingulate, Inc. CING, was a guest on Benzinga’s All Access on August 22, 2022.

Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.


Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksInterviewGeneralBenzinga All AccessCingulate Therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!